Divergent effects of castration on prostate cancer in TRAMP mice: Possible implications for therapy

Clinical Cancer Research

Volumn 14, Issue 10, 2008, Pages 2936-2943

  Tang, Yao ^a   Wang, Linbo ^a   Goloubeva, Olga ^b   Khan, Mohammad Afnan ^a   Zhang, Bin ^a   Hussain, Arif ^a,b,c  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; GLUCOSE REGULATED PROTEIN 78; MYC PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; VIRUS LARGE T ANTIGEN; TUMOR MARKER;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CASTRATION; CONTROLLED STUDY; HISTOPATHOLOGY; HORMONAL REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIMIAN VIRUS 40; ADENOCARCINOMA; ANIMAL; C57BL MOUSE; IMAGE PROCESSING; MALE; METABOLISM; PATHOLOGY; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; TRANSGENIC MOUSE; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; CASTRATION; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 49649110694     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4925     Document Type: Article

References (27)

1. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA1995;92:3439-43.
2. Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-102.
3. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 1999;2:70-5.
4. Laplan-Lefko PJ, ChenTM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a preclinical transgenic mouse model. Prostate 2003;55:219-37.
5. Gleave M, Miyake H, Chi K. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemother Pharmacol 2005;56:s47-57.
6. Tang Y, Khan MA, Goloubeva 0, et al. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 2006;12:169-74.
7. Oyama N, Ponde DE, Dence C, Kim J, Tai YC, Welch MJ. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 2004;45:519-25.
8. Letsch M, Schally AV, Busto R, Bajo AM, Vargo JL. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci USA 2003;100:1250-5.
9. de Pinieux G, Legrier ME, Poirson-Bichat F, et al. Clinical and experimental progression of a new mode of human prostate cancer and therapeutic approach. Am J Pathol 2001;159:753-64.
10. Gingrich JR, Barrios RJ, Kattan MW, Mahm HS, Finegoid MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997;57:4687-91.
11. Johnson MA, Iversen P, Schwier P, et al. Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Prostate 2005; 62:322-38.
12. Shappell SB, Thomas GV, Roberts RL, et al. Prostate pathology of genetically engineered mice: definition and classification. The consensus report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64:2270-305.
13. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 1991;48:189-93.
14. Ruizeveld de Winter JA, Janssen PL, Sleddens HM, et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994;144:735-46.
15. Dai MS, Jin Y, Gallegos JR, Lu H. Balance of yin and yang: ubiquitylation-mediated regulation of p53 and c-Myc. Neoplasia 2006;8:630-44.
16. Li J, Lee AS. Stress induction of GRP78/Bip and its role in cancer. Curr Mol Med 2006;6:45-54.
17. Pootrakul L, Datar RH, Shi SR, et al. Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin Cancer Res 2006;12:5987-93.
18. Catz SD, Johnson JL. Bcl-2 in prostate cancer: a minireview. Apoptosis 2003;8:29-37.
19. Lopez-Diazguerrero ME, Lopez-Araiza H, Xonde-Perezprina JC, et al. Bcl-2 protect against oxidative stress while inducing premature senescence. Free Radic Biol Med 2006;40:1161-9.
20. Cho NH, Part YK, Kim YT, Yang H, Kim SK. Lifetime expression of stem cell markers in the uterine endometrium. Fertil Steril 2004;81:403-7.
21. McDonnell TJ, Deane N, Piatt FM, et al. Bcl-2-immunoglobin transgenic mice demonstrate extended B cell survival and follicular lympho-proliferation. Cell 1989;57:79-88.
22. Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams JM. Constitutive bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci U S A 1999;96:14943-8.
23. Eng MH, Charles LG, Ross BD, et al. Early castration reduces prostatic carcinogenesis in transgenic mice. Urology 1999;54:1112-9.
24. Adam JM, Cory S. The bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-37.
25. Tassone P, Tagliaferri P, Fulciniti TM, Di Martino MT, Venuta S. Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: experimental models and translational issue. Curr Pharm Des 2007;13:487-96.
26. Leonetti C, Zupi G. Targeting different signaling pathways with antisense oligonucleotides combination for cancer therapy. Curr Pharm Des 2007;13:463-70.
27. Chi KN. Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer. World J Urol 2005;23:33-7.